Skip to content

Measurement of Acute Metabolite Changes Following Consumption of Microalgae Drinks

Measurement of Acute Metabolite Changes Following Consumption of Unprocessed and Processed Microalgae: A Randomized Crossover Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07791420
Enrollment
20
Registered
2026-08-28
Start date
2026-09-01
Completion date
2027-12-31
Last updated
2026-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Protein Absorption and Amino Acid Availability, Metabolomics

Keywords

Protein absorption, Amino acid availability, Metabolomics, Processing, Microalgae, Acute

Brief summary

Protein consumption is essential for various physiological processes, with microalgae and plant proteins gaining increasing attention due to their health benefits. To better understand how different protein types and processing methods impact health outcomes, this study aims to analyse the metabolite changes in response to different protein sources.

Detailed description

This study is a randomised crossover trial involving 16 participants. It comprises one screening visit and five test visits, during which participants will consume intervention drinks containing primarily (1) maltodextrin, (2) whey protein isolate, (3) soy protein isolate, (4) bead-milled microalgae, or (5) non-bead-milled microalgae in a randomised order. The study aims to investigate and compare acute postprandial metabolite responses following the consumption of bead-milled and non-bead-milled microalgae, as well as whey and soy protein isolates, in Singaporean adults.

Interventions

DIETARY_SUPPLEMENTBead-milled microalgae

Consume a 400 mL drink containing 20 g protein equivalent of bead-milled microalgae

DIETARY_SUPPLEMENTNon-bead-milled microalgae

Consume a 400 mL drink containing 20 g protein equivalent of non-bead-milled microalgae

DIETARY_SUPPLEMENTWhey protein isolate

Consume a 400 mL drink containing 20 g protein equivalent of whey protein isolate

DIETARY_SUPPLEMENTSoy protein isolate

Consume a 400 mL drink containing 20 g protein equivalent of soy protein isolate

DIETARY_SUPPLEMENTMaltodextrin (Placebo)

Consume a 400 mL drink containing maltodextrin matched for the energy content of 20 g protein

Sponsors

National University of Singapore
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
21 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* English-literate and able to give informed consent * Singaporean Chinese Adults aged 21 to 60 (inclusive) * Body mass index of 18.5 to 23.0 kg/m\^2 (inclusive) * Healthy (Based on results from screening session)

Exclusion criteria

* Currently participating in another clinical study that involves altering the regular diet and/or involves consuming a dietary supplement or investigated food product as an intervention * High blood pressure (≥ 140/90 mmHg) * Underlying health conditions that may affect metabolic functions * Consuming amino acid or protein supplements, or protein drinks, regularly (i.e., more than three times a week) for the past 3 months, and not willing to discontinue usage 3 months before and during the study duration * Weight change \> 3 kg in the past 3 months * Weight \< 50 kg * Exercising vigorously over the past 3 months (i.e., engaging in high-intensity exercises for more than 3 hours a week, where high-intensity exercises leave one out of breath and unable to talk or sing during the workout) * Current smokers or have quit smoking for less than 5 years * Drinking \> 2 alcoholic drinks per day (i.e., one drink is defined as either 150 ml of wine, 340 ml of beer/cider or 45 ml of distilled spirit) * If drinking ≤ 2 alcoholic drinks per day, not willing to stop consumption of alcoholic beverages two days before and on the day of the test visits * Not willing to stop consumption of caffeinated beverages 10 to 12 houFrs before and on the day of the test visits * Currently on a specialised diet (e.g., Halal, vegetarian, vegan, weight loss diet) * Had serious food allergies in the past, or having intolerance, sensitivities or allergies to any of the following: seaweed or algae and their derived products, milk/dairy products (e.g., whey), starch/starch-derived products (e.g., rice, corn, wheat, potato), soy/soy-derived products, gluten, eggs, nuts, peanuts, fish and crustaceans * Disease or impairment of the kidney and/or liver\* * Currently diagnosed with diabetes\*, gastrointestinal issues (e.g., lactose intolerance, irritable bowel syndrome), gout and/or G6PD deficiency * Taking antibiotics 2 weeks prior to study participation * Taking anti-hypertensive or cholesterol-lowering drugs for less than 3 years unless medically declared by an official doctor to be in stable condition * Poor peripheral venous access based on past experiences with blood drawing * Individuals with anemia and/or blood clotting disorders * Donated blood within the 12 weeks prior to study participation * Individuals with pacemaker or related electrical medical devices * Pregnant, lactating, or planning pregnancy in the next 6 months

Design outcomes

Primary

MeasureTime frameDescription
Changes in metabolites found in plasma (plasma metabolomics)Baseline, 15, 30, 45, 60, 90, 120, 180, 240, 300 minutesTargeted metabolomics profiling of plasma will be conducted using liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS)
Changes in metabolites found in urine (urinary metabolomics)Baseline and 300 minutesTargeted metabolomics profiling of urine will be conducted liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS)

Secondary

MeasureTime frameDescription
AppetiteBaseline, 60, 120, 180, 240, 300 minutesThe Appetite Visual Analogue Scale (VAS) questionnaire will be administered, with participants rating five appetite-related outcomes, i.e. desire to eat, hunger, fullness, satisfaction, and prospective food consumption. Each response will be measured on a 100-mm visual analogue scale and scored from 0 to 100, with higher scores indicate a greater intensity of the outcomes being assessed, i.e. greater desire to eat, greater hunger, greater fullness, greater satisfaction, or a greater perceived amount of food that could be consumed.

Countries

Singapore

Contacts

CONTACTMarven Ng, B.Sc.
ngmarven@u.nus.edu(+65) 8816 9977
PRINCIPAL_INVESTIGATORJung Eun Kim, Ph.D., R.D.

National University of Singapore, Department of Food Science and Technology

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 2, 2026